Bristol-Myers Squibb and the ADAP Crisis Task Force (ACTF) have announced an enhanced agreement to provide antiretroviral medicines to people living with HIV and AIDS in the US.
The biopharmaceutical firm’s support for AIDS drug assistance programmes (ADAPs) builds on an agreement signed in March 2010.
Bristol-Myers Squibb has worked with the ACTF have since its inception in 2002, and will provide access to HIV medications such as Reyataz (atazanavir) and Sustiva (efavirenz).
The alliance also covers the patient assistance programme, which offers people living with HIV/AIDS multiple ways to obtain medicine at reduced or no cost through the Bristol-Myers Squibb “Access Virology” programme.
The programme also allows for the fast-tracking of patients currently on an ADAP waiting list.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData